@entity136 combined with @entity900 as neoadjuvant chemotherapy in stage IB-IIIA XXXX .

@entity1 @entity137 @entity417 @entity882 @entity5 @entity1149 @entity900 @entity1398 @entity136
This single-arm, multicenter, phase II study examined the objective response rate and @entity137 after neoadjuvant chemotherapy with @entity136 and @entity900 in @entity1 with stage IB-IIIA @entity1149 . Treatment consisted of three 21-day cycles of @entity136 (1000 mg/m(2)) on days 1 and 8 and @entity900 (75 mg/m(2)) on day 1 of each cycle. Surgery was performed 4-5 weeks after day 1 of the last cycle of study therapy. A total of 52 @entity1 from five investigative sites in Russia were enrolled in the study, of which 50 (96.2%) received study therapy. Of the 49 @entity1 who were evaluable for response, six (12.2%) had a complete response and 16 (32.7%) had a partial response, resulting in an overall response rate of 44.9%. Disease progression occurred in four out of the 49 (8.2%) @entity1 . Radical @entity5 resection was performed in 38 out of the 49 (77.6%) @entity1 . A total of 41 @entity1 were assessed for a pathological complete response, of which four (9.8%) @entity1 had pathological complete @entity5 regression. Postsurgical restaging was performed in 36 out of the 41 (87.8%) @entity1 . @entity5 downstaging occurred in 16 out of the 36 (44.4%) @entity1 . Grade 3/4 @entity1398 and @entity882 were experienced by 28.0%/6.0% @entity1 and 6.0%/2.0% @entity1 , respectively. Grade 3 @entity417 occurred in 4.0% of the @entity1 . Nonhematological @entity137 was mild. Overall mortality was 30.0% (15 out of 50 @entity1 ), predominantly from progressive disease. The 1-year overall survival rate was 74.4% (95% confidence interval: 61.3-87.6%). Neoadjuvant chemotherapy with @entity136 and @entity900 showed a good safety profile with an encouraging possibility of curative surgery in @entity1 with early-stage @entity1149 .
